Oveporexton and the Orexin Era: Mechanism-Targeted Therapy for Narcolepsy Type 1

Bottom Line: On August 5, 2026, the FDA approved oveporexton (Orzeyful, Takeda), an oral orexin receptor 2 (OX2R)-selective agonist, for adults with narcolepsy type 1 (NT1) — the first therapy that acts directly on the deficient orexin signaling pathway rather than on downstream symptoms. The recommended dose is 1 mg or 2 mg twice daily, both doses taken in the morning hours: the first after awakening, the second 3–5 hours later (maximum 4 mg/day). Phase 2b data showed Maintenance of Wakefulness Test (MWT) gains of 23.5–25.4 minutes at the 2-mg twice-daily doses versus a 1.2-minute decline on placebo, and the label's per-arm phase 3 tables show placebo-corrected MWT gains of roughly 13–20 minutes, with sleepiness, cataplexy, and attention endpoints all improving. Legacy agents remain relevant, but for confirmed orexin-deficient NT1, the treatment paradigm has changed.

The Orexin Lesion: A Receptor-Level Problem

Narcolepsy type 1 is caused by selective loss of hypothalamic orexin (hypocretin)-producing neurons — a process presumed, and strongly supported by immunogenetic evidence, to be autoimmune-mediated, though not definitively established in every patient. The result is a pentad familiar to every neurologist: excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic hallucinations, and disrupted nocturnal sleep. Crucially, while the orexin neurons die, their target receptors survive. OX2R — the receptor most responsible for consolidated wakefulness — remains intact and pharmacologically accessible throughout the brain (reviews: Drug Discov Ther 2026; Front Neurosci 2025).

This framing matters for how we describe the new drug to patients. Oveporexton does not restore orexin neurons, and it does not modify the presumed autoimmune injury. It is receptor agonism downstream of the lost neurons — replacing the missing signal, not the missing cells. "Mechanism-targeted" is the accurate term; "disease-modifying" is not. The distinction is the difference between insulin and an immunotherapy for type 1 diabetes: profound clinical benefit, honest mechanistic humility.

The Road Here: Three Molecules and a Hepatotoxicity Lesson

The class took three molecules to reach approval. Danavorexton, an intravenous OX2R agonist, established proof of concept but was impractical for chronic use. TAK-994, the first oral agent, delivered striking efficacy in a phase 2 trial (TAK-994-1501, NEJM 2023; DOI 10.1056/NEJMoa2301940): among 73 patients randomized to 30, 90, or 180 mg twice daily or placebo, least-squares mean MWT sleep-latency changes at week 8 were 23.9, 27.4, and 32.6 minutes versus −2.5 minutes on placebo (P<0.001 for all comparisons), with weekly cataplexy rates of 0.27, 1.14, and 0.88 versus 5.83 on placebo. But the trial and its extension were terminated early for hepatic adverse events: clinically important liver-enzyme elevations occurred in 5 patients, and drug-induced liver injury meeting Hy's law criteria occurred in 3. TAK-994 deserves explicit billing in this story for two reasons — it proved the class could normalize wakefulness in NT1, and it defined the safety question every subsequent orexin agonist must answer.

Oveporexton (TAK-861) is roughly 10-fold more potent at OX2R (EC50 2.5 nM in preclinical characterization; Sci Rep 2024), allowing efficacy at milligram doses — a plausible margin against the dose-dependent hepatotoxicity that ended TAK-994.

Phase 2b: The Peer-Reviewed Anchor

The pivotal peer-reviewed evidence is the phase 2b trial (TAK-861-2001, Dauvilliers et al., NEJM 2025;392:1905-1916; DOI 10.1056/NEJMoa2405847). A total of 112 participants with NT1 were randomized: oveporexton 0.5 mg twice daily (n=23), 2 mg twice daily (n=21), 2 mg followed by 5 mg daily (n=23), 7 mg once daily (n=23), or placebo (n=22), for 8 weeks.

The results reset expectations for what an NT1 trial can show:

• Wakefulness (MWT, primary endpoint): mean change in average sleep latency of +12.5, +23.5, +25.4, and +15.0 minutes across the four dose arms versus −1.2 minutes on placebo (adjusted P≤0.001 for all comparisons). With normal MWT defined as ≥20 minutes, the 2-mg twice-daily regimens moved group means into the normative range. Among therapies approved for NT1 before the orexin agonists, no drug class approaches MWT gains of this magnitude — although TAK-994 itself had matched or exceeded them before its discontinuation.
• Sleepiness (ESS): changes of −8.9, −13.8, −12.8, and −11.3 versus −2.5 on placebo (adjusted P≤0.004 for all).
• Cataplexy: weekly rates at week 8 of 4.24, 3.14, 2.48, and 5.89 versus 8.76 on placebo — but adjusted P<0.05 only for the 2-mg twice-daily and 2-mg→5-mg arms. The honest reading: anticataplectic benefit was dose-schedule-dependent, and 7 mg once daily underperformed. The dose schedule appears to matter for REM-dissociation phenomena — though the reason is not established, and the approved regimen is not spaced around the clock: both doses are taken in the morning hours, 3–5 hours apart. Whatever the pharmacodynamic explanation, the twice-daily regimen was the one carried into phase 3.

Phase 3: FirstLight, RadiantLight, and the Approval

The approval rests on two randomized, double-blind, placebo-controlled 12-week trials enrolling 273 participants aged 16–65 across 19 countries: FirstLight (TAK-861-3001; n=168; 2 mg twice daily, 1 mg twice daily, or placebo) and RadiantLight (TAK-861-3002; n=105; 2 mg twice daily or placebo). Although the trials enrolled from age 16, the approved indication is adults, and safety and effectiveness in patients under 18 are not established.

Per-arm phase 3 efficacy data are now available in the prescribing information, even though the primary peer-reviewed publication is still pending. Per the label tables: in FirstLight, least-squares mean MWT change was −1.3 minutes on placebo versus +12.5 minutes with 1 mg twice daily and +15.9 minutes with 2 mg twice daily; in RadiantLight, −1.0 minutes on placebo versus +19.1 minutes with 2 mg twice daily. ESS change and weekly cataplexy rate are likewise tabulated per arm in the label. The broader topline claims below come from Takeda's World Sleep 2025 release and should still be treated as press-release-level pending the full paper: both trials met all primary and secondary endpoints, with reported p-values of <0.001 across all doses at week 12; close to 85% of participants on the 2/2-mg regimen achieved ESS scores comparable to healthy individuals (≤10); median cataplexy reduction from baseline exceeded 80%; and cataplexy-free days rose from 0 at baseline to 4–5 per week at week 12. On the Patient Global Impression of Change, 97% of treated participants reported improvement, and more than 95% of completers enrolled in the ongoing long-term extension.

The FDA approved oveporexton on August 5, 2026, as Orzeyful for adults with NT1, following Breakthrough Therapy designation and Priority Review. The recommended dosage is 1 mg or 2 mg twice daily — the first dose upon awakening, the second 3–5 hours later, with a maximum total daily dose of 4 mg. The agency called it the "first medicine approved for narcolepsy type 1 as a complete disorder" — language reflecting improvement not only in sleepiness and cataplexy but also, per the FDA announcement and phase 3 program, in sleep paralysis, hallucinations, and disrupted nighttime sleep. Those broad-spectrum claims should be cited at that level; endpoint-specific peer-reviewed data for the ancillary symptoms are not yet available.

Beyond sleepiness and cataplexy: attention and cognition

Two peer-reviewed analyses extend the picture. In the phase 3 trials, a clinically meaningful attention improvement (≥2 fewer Psychomotor Vigilance Task lapses) at day 84 was achieved by 66.9% versus 25.7% of placebo in FirstLight and 57.6% versus 17.6% in RadiantLight (both P≤0.0001; DOI 10.1007/s43441-026-01025-8). A secondary analysis of the phase 2b cognition data (JAMA Neurol 2026;83:145-152; DOI 10.1001/jamaneurol.2025.4825) reported placebo-adjusted PVT lapse reductions across doses — for example, −10.77 (95% CI, −16.74 to −4.79) in the 0.5-mg twice-daily arm. For patients whose chief functional complaint is "brain fog" rather than sleep attacks, these are decision-relevant data.

Safety and Practical Prescribing

In the phase 2b trial, the most common adverse events were insomnia (48% of participants, most cases resolving within 1 week), urinary urgency (33%), and urinary frequency (32%), with no hepatotoxic effects observed (NEJM 2025). At the 2-mg twice-daily dose, label-level rates reported with the approval are higher for some events: insomnia in 60%, urinary frequency in 58%, urinary urgency in 16%, plus salivary hypersecretion and creatine phosphokinase (CPK) elevations.

The hepatic question deserves precision. There has been no TAK-994-like drug-induced liver injury signal with oveporexton to date — no Hy's law cases, no hepatotoxic effects in the phase 2b publication. But this should not be flattened into "no hepatotoxicity signal": the label-level safety information includes CPK elevations, and two cases with markedly elevated CPK and transaminases were reported in the development program. Given the class history, clinicians should follow whatever laboratory monitoring the final label specifies rather than assume none is needed.

Practical points for the prescriber:

• Dose at 1 mg or 2 mg twice daily — first dose upon awakening, second dose 3–5 hours later (both in the morning hours, not spaced across the day); maximum 4 mg/day.
• Avoid coadministration with strong CYP3A inhibitors, per the FDA announcement.
• Avoid use in severe hepatic impairment and in dialysis-level renal impairment.
• The label notes abuse and misuse potential; the FDA has recommended scheduling under the Controlled Substances Act, and the DEA scheduling decision is pending — state only what the label says until then.
• Safety and efficacy are not established in patients under 18 (phase 3 enrolled from age 16, but the indication is adults); a pregnancy registry has been established, and exposure in pregnancy should be reported.
• Counsel patients that early insomnia is common and usually transient, and that urinary symptoms are expected class effects.
• Long-term (>1 year) safety rests on the ongoing extension study; cardiovascular and blood-pressure surveillance expectations should follow the final label. There are no head-to-head data against any active comparator.

Where It Fits: Repositioning the Existing Armamentarium

The right contrast with legacy agents is mechanistic, not a caricature of their indications. Modafinil/armodafinil and solriamfetol are wake-promoters for EDS; pitolisant is approved for EDS or cataplexy in adults with narcolepsy; the oxybates are approved for both EDS and cataplexy and also consolidate nocturnal sleep — at the cost of sodium load (for sodium oxybate), CNS depression, nightly dosing logistics, and REMS requirements. Antidepressants for cataplexy remain off-label. What none of these do is act on the orexin system itself. Oveporexton is the first single agent targeting the full NT1 symptom spectrum through the pathway whose failure defines the disease (reviews: Clin Pharmacol 2026; J Clin Med 2025).

Candidate scenarios where an orexin agonist plausibly becomes first-line or replaces polypharmacy:

• Newly diagnosed orexin-deficient NT1 — a single mechanism-targeted agent versus sequential stacking of stimulant, oxybate, and anticataplectic.
• Patients on stimulant + oxybate + SNRI combinations — simplification, if response is adequate.
• Oxybate-intolerant or oxybate-ineligible patients — including those for whom sodium load or nightly awakening dosing is untenable.

Two hard caveats. First, Orzeyful's indication is NT1 only: oveporexton has no data supporting use in narcolepsy type 2 or idiopathic hypersomnia, where orexin neurons are not deficient. The class is a different matter — other OX2R agonists are actively generating data in non-orexin-deficient hypersomnias, most prominently alixorexton (formerly ALKS-2680, Alkermes), which is in phase 3 for NT2 and phase 2 for idiopathic hypersomnia in addition to NT1. Until those trials read out, prescribing an orexin agonist outside orexin-deficient NT1 is extrapolation, not evidence-based practice. Second, secure the diagnosis before switching. CSF orexin measurement is confirmatory but is not obtained in most routine practice; in the real world, the diagnosis usually rests on unambiguous cataplexy plus supportive PSG/MSLT findings — that combination is acceptable, but "possible NT2 with atypical spells" is not a basis for prescribing an OX2R agonist. Finally, the class is bigger than the drug: with alixorexton and others in late development, formulary and comparative-effectiveness questions will arrive quickly.

What the General Neurologist Needs to Know

• Oveporexton (Orzeyful) was FDA-approved August 5, 2026, for adults with NT1 — the first drug acting directly on the deficient orexin pathway (receptor agonism, not neuronal restoration or immunomodulation). Recommended dosing is 1 mg or 2 mg twice daily: first dose on awakening, second 3–5 hours later; maximum 4 mg/day.
• Magnitude matters: phase 2b MWT gains of ~23–25 minutes (versus −1.2 on placebo), label per-arm phase 3 MWT gains of +12.5 to +19.1 minutes (versus −1.3 and −1.0 on placebo), and topline reports of ~85% reaching ESS ≤10 exceed anything achieved by previously approved NT1 therapies; many patients approach normative wakefulness.
• Cataplexy improves substantially (>80% median reduction; 4–5 cataplexy-free days/week in phase 3 toplines), potentially displacing oxybate/antidepressant combinations — per-arm data are in the label, with the primary peer-reviewed publication still pending.
• Expect early transient insomnia (60% at the 2-mg dose) and urinary symptoms; no TAK-994-like liver-injury signal to date, but CPK elevations are on the label and the class history justifies adherence to label monitoring guidance.
• Confirm orexin-deficient NT1 (CSF orexin, or clear cataplexy with supportive PSG/MSLT) before prescribing; oveporexton has no NT2/idiopathic hypersomnia data, though other class members (alixorexton) are being trialed there.
• Avoid strong CYP3A inhibitors, severe hepatic impairment, and dialysis-level renal impairment; pediatric use is not established; DEA scheduling is pending.

Conclusion

For twenty-five years, we have known exactly what NT1 is — the loss of a small, specific neuronal population — while treating it with drugs that never touched that fact. Oveporexton closes that gap at the receptor level. The phase 2b trial (NEJM 2025) provides peer-reviewed evidence of wakefulness gains without precedent among approved NT1 therapies, the phase 3 program, label efficacy tables, and FDA approval extend the claim across the symptom spectrum, and the TAK-994 experience (NEJM 2023) supplies both the proof of concept and the reason for continued pharmacovigilance. What remains is the unglamorous work: confirming the full phase 3 results in a peer-reviewed publication, accumulating long-term extension safety data, defining monitoring in practice, and learning where legacy agents still earn their place. But the direction is settled. NT1 treatment is now organized around its mechanism — and the general neurologist should be prepared to identify the orexin-deficient patients who stand to benefit first.